@article{3086630,
    title = "Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation",
    author = "Kaaks, R. and Fortner, R.T. and Hüsing, A. and Barrdahl, M. and Hopper, M. and Johnson, T. and Tjønneland, A. and Hansen, L. and Overvad, K. and Fournier, A. and Boutron-Ruault, M.-C. and Kvaskoff, M. and Dossus, L. and Johansson, M. and Boeing, H. and Trichopoulou, A. and Benetou, V. and La Vecchia, C. and Sieri, S. and Mattiello, A. and Palli, D. and Tumino, R. and Matullo, G. and Onland-Moret, N.C. and Gram, I.T. and Weiderpass, E. and Sánchez, M.-J. and Navarro Sanchez, C. and Duell, E.J. and Ardanaz, E. and Larranaga, N. and Lundin, E. and Idahl, A. and Jirström, K. and Nodin, B. and Travis, R.C. and Riboli, E. and Merritt, M. and Aune, D. and Terry, K. and Cramer, D.W. and Anderson, K.S.",
    journal = "International Journal  of Cancer",
    year = "2018",
    volume = "143",
    number = "3",
    pages = "515-526",
    publisher = "Wiley-Liss, Inc.",
    issn = "0020-7136",
    doi = "10.1002/ijc.31335",
    keywords = "autoantibody;  CA 125 antigen;  cancer antibody;  oncoprotein;  protein CTAG1A;  protein CTAG2;  protein NUDT11;  protein p53;  tumor marker;  unclassified drug;  autoantibody;  CA 125 antigen;  tumor antigen;  tumor marker, adult;  aged;  area under the curve;  Article;  blood sampling;  cancer grading;  case control study;  cohort analysis;  controlled study;  diagnostic test accuracy study;  early cancer diagnosis;  electrochemiluminescence;  enzyme linked immunosorbent assay;  false positive result;  female;  follow up;  human;  logistic regression analysis;  major clinical study;  multicenter study;  ovary cancer;  panel study;  priority journal;  prospective study;  quantitative analysis;  sensitivity and specificity;  blood;  immunology;  middle aged;  ovary tumor;  procedures;  risk factor, Adult;  Aged;  Antigens, Neoplasm;  Autoantibodies;  Biomarkers, Tumor;  CA-125 Antigen;  Case-Control Studies;  Early Detection of Cancer;  Female;  Humans;  Middle Aged;  Ovarian Neoplasms;  Prospective Studies;  Risk Factors;  Sensitivity and Specificity",
    abstract = "Immuno-proteomic screening has identified several tumor-associated autoantibodies (AAb) that may have diagnostic capacity for invasive epithelial ovarian cancer, with AAbs to P53 proteins and cancer-testis antigens (CTAGs) as prominent examples. However, the early detection potential of these AAbs has been insufficiently explored in prospective studies. We performed ELISA measurements of AAbs to CTAG1A, CTAG2, P53 and NUDT11 proteins, for 194 patients with ovarian cancer and 705 matched controls from the European EPIC cohort, using serum samples collected up to 36 months prior to diagnosis under usual care. CA125 was measured using electrochemo-luminiscence. Diagnostic discrimination statistics were calculated by strata of lead-time between blood collection and diagnosis. With lead times ≤6 months, ovarian cancer detection sensitivity at 0.98 specificity (SE98) varied from 0.19 [95% CI 0.08–0.40] for CTAG1A, CTAG2 and NUDT1 to 0.23 [0.10–0.44] for P53 (0.33 [0.11–0.68] for high-grade serous tumors). However, at longer lead-times, the ability of these AAb markers to distinguish future ovarian cancer cases from controls declined rapidly; at lead times >1 year, SE98 estimates were close to zero (all invasive cases, range: 0.01–0.11). Compared to CA125 alone, combined logistic regression scores of AAbs and CA125 did not improve detection sensitivity at equal level of specificity. The added value of these selected AAbs as markers for ovarian cancer beyond CA125 for early detection is therefore limited. © 2018 UICC"
}